Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
received:
30
11
2023
accepted:
19
04
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
10
6
2024
Statut:
epublish
Résumé
It is recommended that the adjuvant Montanide ISA 720 VG be used at a concentration of 70% v/v. At this concentration, Montanide causes at the site of immunization a local granuloma that can last for several weeks. To determine the safety and protective efficacy of a Chlamydia muridarum MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide (70%, 50%, 30% and 10%), BALB/c (H-2
Identifiants
pubmed: 38858418
doi: 10.1038/s41541-024-00880-6
pii: 10.1038/s41541-024-00880-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104Subventions
Organisme : NIAID NIH HHS
ID : U19 AI144184
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI144184
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
CDC. Division of STD Prevention, 1–168 (U.S. Department of Health and Human Services, Atlanta, 2021).
Schachter, J. & Dawson, C. R. Human Chlamydial Infections, 273 (PSG Pub. Co., 1978).
Beem, M. O. & Saxon, E. M. Respiratory-tract colonization and a distinctive pneumonia syndrome in infants infected with Chlamydia trachomatis. N. Engl. J. Med 296, 306–310 (1977).
pubmed: 831128
doi: 10.1056/NEJM197702102960604
O’Connell, C. M. & Ferone, M. E. Chlamydia trachomatis genital Infections. Micro. Cell 3, 390–403 (2016).
doi: 10.15698/mic2016.09.525
Westrom, L., Joesoef, R., Reynolds, G., Hagdu, A. & Thompson, S. E. Pelvic inflammatory disease and fertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex. Transm. Dis. 19, 185–192 (1992).
pubmed: 1411832
doi: 10.1097/00007435-199207000-00001
Plummer, F. A. et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163, 233–239 (1991).
pubmed: 1988508
doi: 10.1093/infdis/163.2.233
Silva, J., Cerqueira, F. & Medeiros, R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch. Gynecol. Obstet. 289, 715–723 (2014).
pubmed: 24346121
doi: 10.1007/s00404-013-3122-3
Ito, J. I. et al. Pneumonia due to chlamydia trachomatis in an immunocompromised adult. N. Engl. J. Med. 307, 95–98 (1982).
pubmed: 6283347
doi: 10.1056/NEJM198207083070205
Harrison, H. R., Taussig, L. M. & Fulginiti, V. A. Chlamydia trachomatis and chronic respiratory disease in childhood. Pediatr. Infect. Dis. 1, 29–33 (1982).
pubmed: 7177892
doi: 10.1097/00006454-198201000-00008
Burton, M. J. et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 365, 1321–1328 (2005).
pubmed: 15823382
doi: 10.1016/S0140-6736(05)61029-X
Brunham, R. C., Pourbohloul, B., Mak, S., White, R. & Rekart, M. L. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J. Infect. Dis. 192, 1836–1844 (2005).
pubmed: 16235186
doi: 10.1086/497341
de la Maza, M. A. & de la Maza, L. M. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 13, 119–127 (1995).
pubmed: 7762268
doi: 10.1016/0264-410X(95)80022-6
Rockey, D. D., Wang, J., Lei, L. & Zhong, G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev. Vaccines 8, 1365–1377 (2009).
pubmed: 19803759
doi: 10.1586/erv.09.98
Farris, C. M. & Morrison, R. P. Vaccination against Chlamydia genital infection utilizing the murine C muridarum model. Infect. Immun. 79, 986–996 (2011).
pubmed: 21078844
doi: 10.1128/IAI.00881-10
Carmichael, J. R., Pal, S., Tifrea, D. & de la Maza, L. M. Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine. Vaccine 29, 5276–5283 (2011).
pubmed: 21609745
pmcid: 3139009
doi: 10.1016/j.vaccine.2011.05.013
de la Maza, L. M., Zhong, G. & Brunham, R. C. Update on Chlamydia trachomatis vaccinology. Clin. Vaccine Immunol. 24, e00543 (2017).
Phillips, S., Quigley, B. L. & Timms, P. Seventy years of Chlamydia vaccine research - Limitations of the past and directions for the future. Front. Microbiol. 10, 70 (2019).
pubmed: 30766521
pmcid: 6365973
doi: 10.3389/fmicb.2019.00070
Pal, S., Peterson, E. M. & de la Maza, L. M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73, 8153–8160 (2005).
pubmed: 16299310
pmcid: 1307068
doi: 10.1128/IAI.73.12.8153-8160.2005
Sun, G., Pal, S., Weiland, J., Peterson, E. M. & de la Maza, L. M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27, 5020–5025 (2009).
pubmed: 19446590
pmcid: 2741729
doi: 10.1016/j.vaccine.2009.05.008
Kari, L. et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182, 8063–8070 (2009).
pubmed: 19494332
doi: 10.4049/jimmunol.0804375
Tifrea, D. F., Pal, S., Popot, J. L., Cocco, M. J. & de la Maza, L. M. Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum. J. Immunol. 192, 5201–5213 (2014).
pubmed: 24778450
doi: 10.4049/jimmunol.1303392
Teng, A. et al. Proteomic identification of immunodominant chlamydial antigens in a mouse model. J. Proteom. 77, 176–186 (2012).
doi: 10.1016/j.jprot.2012.08.017
de la Maza, L. M., Pal, S., Olsen, A. W., and Follmann, F. Chlamydia Vaccines, 339–383 (Caister Academic Press, 2020).
Abraham, S. et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 19, 1091–1100 (2019).
pubmed: 31416692
doi: 10.1016/S1473-3099(19)30279-8
Caldwell, H. D. & Schachter, J. Antigenic analysis of the major outer membrane protein of Chlamydia spp. Infect. Immun. 35, 1024–1031 (1982).
pubmed: 7068209
pmcid: 351150
doi: 10.1128/iai.35.3.1024-1031.1982
Stephens, R. S., Sanchez-Pescador, R., Wagar, E. A., Inouye, C. & Urdea, M. S. Diversity of Chlamydia trachomatis major outer membrane protein genes. J. Bacteriol. 169, 3879–3885 (1987).
pubmed: 3040664
pmcid: 213681
doi: 10.1128/jb.169.9.3879-3885.1987
Sun, G. et al. Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis. J. Bacteriol. 189, 6222–6235 (2007).
pubmed: 17601785
pmcid: 1951919
doi: 10.1128/JB.00552-07
Baehr, W. et al. Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes. Proc. Natl Acad. Sci. USA 85, 4000–4004 (1988).
pubmed: 2453883
pmcid: 280348
doi: 10.1073/pnas.85.11.4000
Stephens, R. S., Wagar, E. A. & Schoolnik, G. K. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med 167, 817–831 (1988).
pubmed: 2450954
doi: 10.1084/jem.167.3.817
Ortiz, L. et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J. Immunol. 157, 4554–4567 (1996).
pubmed: 8906834
doi: 10.4049/jimmunol.157.10.4554
Pulendran, B., Arunachalam, P. S. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
pubmed: 33824489
pmcid: 8023785
doi: 10.1038/s41573-021-00163-y
Plotkin, S. A., Orenstein, W. A. & Offit, P. A. Plotkin’s Vaccines, 7th edn (Elsevier, 2018).
Morrison, S. G. & Morrison, R. P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175, 7536–7542 (2005).
pubmed: 16301662
doi: 10.4049/jimmunol.175.11.7536
Morrison, R. P., Feilzer, K. & Tumas, D. B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect. Immun. 63, 4661–4668 (1995).
pubmed: 7591120
pmcid: 173669
doi: 10.1128/iai.63.12.4661-4668.1995
Farris, C. M., Morrison, S. G. & Morrison, R. P. CD4 + T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect. Immun. 78, 4374–4383 (2010).
pubmed: 20660610
pmcid: 2950360
doi: 10.1128/IAI.00622-10
Tifrea, D. F. et al. Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant. Vaccine 38, 4412–4422 (2020).
pubmed: 32386746
pmcid: 8846571
doi: 10.1016/j.vaccine.2020.04.065
Pal, S. et al. Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge. NPJ Vaccines 5, 90 (2020).
pubmed: 33083025
pmcid: 7530680
doi: 10.1038/s41541-020-00239-7
Pal, S., Theodor, I., Peterson, E. M. & de la Maza, L. M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69, 6240–6247 (2001).
pubmed: 11553566
pmcid: 98757
doi: 10.1128/IAI.69.10.6240-6247.2001
Pal, S., Davis, H. L., Peterson, E. M. & de la Maza, L. M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect. Immun. 70, 4812–4817 (2002).
pubmed: 12183524
pmcid: 128273
doi: 10.1128/IAI.70.9.4812-4817.2002
Stills, H. F. Jr. Adjuvants and antibody production: dispelling the myths associated with Freund’s complete and other adjuvants. ILAR J. 46, 280–293 (2005).
pubmed: 15953835
doi: 10.1093/ilar.46.3.280
Huijbers, E. J. et al. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund’s in a cancer vaccine targeting ED-B–a prerequisite for clinical development. Vaccine 30, 225–230 (2012).
pubmed: 22079080
doi: 10.1016/j.vaccine.2011.11.010
Melssen, M. M., Fisher, C. T., Slingluff, C. L. & Melief, C. J. M. Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4(+) and CD8( + ) T cells for immunotherapy of cancer. J. Immunother. Cancer 10, 9 (2022).
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S. & Ganne, V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111–118 (2002).
pubmed: 12908518
doi: 10.1586/14760584.1.1.111
Toledo, H. et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19, 4328–4336 (2001).
pubmed: 11457560
doi: 10.1016/S0264-410X(01)00111-6
Saul, A. et al. A human phase 1 vaccine clinical trial of the plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in montanide ISA720 adjuvant. Vaccine 23, 3076–3083 (2005).
pubmed: 15811655
doi: 10.1016/j.vaccine.2004.09.040
Motavalli Khiavi, F. et al. A dual-type L2 11-88 peptide from HPV Types 16/18 formulated in montanide ISA 720 induced strong and balanced Th1/Th2 immune responses, associated with high titers of broad sectrum cross-reactive antibodies in vaccinated mice. J. Immunol. Res. 2018, 9464186 (2018).
Alleva, D. G. et al. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine 39, 6601–6613 (2021).
pubmed: 34642088
pmcid: 8491978
doi: 10.1016/j.vaccine.2021.09.077
Shokri, M., Roohvand, F., Alimohammadian, M. H., Ebrahimirad, M. & Ajdary, S. Comparing Montanide ISA 720 and 50-V2 adjuvants formulated with LmSTI1 protein of Leishmania major indicated the potential cytokine patterns for induction of protective immune responses in BALB/c mice. Mol. Immunol. 76, 108–115 (2016).
pubmed: 27428863
doi: 10.1016/j.molimm.2016.06.010
Miles, A. P. et al. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23, 2530–2539 (2005).
pubmed: 15752840
doi: 10.1016/j.vaccine.2004.08.049
Fox, C. B., Baldwin, S. L., Duthie, M. S., Reed, S. G. & Vedvick, T. S. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 29, 9563–9572 (2011).
pubmed: 21906648
pmcid: 3224191
doi: 10.1016/j.vaccine.2011.08.089
Wagner, H. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev. 61, 243–247 (2009).
pubmed: 19174176
doi: 10.1016/j.addr.2008.12.010
Krieg, A. M. Immune effects and mechanisms of action of CpG motifs. Vaccine 19, 618–622 (2000).
pubmed: 11090712
doi: 10.1016/S0264-410X(00)00249-8
de Gruijter, N. M., Jebson, B. & Rosser, E. C. Cytokine production by human B cells: role in health and autoimmune disease. Clin. Exp. Immunol. 210, 253–262 (2022).
pubmed: 36179248
pmcid: 9985175
doi: 10.1093/cei/uxac090
Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu Rev. Immunol. 20, 709–760 (2002).
pubmed: 11861616
doi: 10.1146/annurev.immunol.20.100301.064842
Girndt, M. et al. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B(R)) compared with HepB-Eng (Engerix-B(R)) and HepB-AS04 (Fendrix(R)) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: results of a randomized, multicenter phase 3 study. Hum. Vaccines Immunother. 18, 2136912 (2022).
doi: 10.1080/21645515.2022.2136912
van Doorn, E., Liu, H., Huckriede, A. & Hak, E. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review. Hum. Vaccines Immunother. 12, 159–169 (2016).
doi: 10.1080/21645515.2015.1071455
Hutchison, S. et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272–1279 (2012).
pubmed: 22106367
pmcid: 3289510
doi: 10.1096/fj.11-184556
Igietseme, J. U., Magee, D. M., Williams, D. M. & Rank, R. G. Role for CD8 + T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. Infect. Immun. 62, 5195–5197 (1994).
pubmed: 7927806
pmcid: 303248
doi: 10.1128/iai.62.11.5195-5197.1994
Poston, T. B. et al. Cervical cytokines associated With Chlamydia trachomatis susceptibility and protection. J. Infect. Dis. 220, 330–339 (2019).
pubmed: 30820577
pmcid: 6581900
doi: 10.1093/infdis/jiz087
Russell, A. N. et al. Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection. J. Infect. Dis. 213, 523–531 (2016).
pubmed: 26347571
doi: 10.1093/infdis/jiv438
Naglak, E. K., Morrison, S. G. & Morrison, R. P. IFNgamma is required for optimal antibody-mediated immunity against genital Chlamydia infection. Infect. Immun. 84, 3232–42 (2016).
Jiang, P. et al. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model. Vaccine 35, 3096–3103 (2017).
pubmed: 28456528
doi: 10.1016/j.vaccine.2017.04.031
Cheng, C., Pal, S., Tifrea, D., Jia, Z. & de la Maza, L. M. A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect. 16, 244–252 (2014).
pubmed: 24291713
doi: 10.1016/j.micinf.2013.11.009
Jones, T. R. et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in aotus monkeys. Vaccine 17, 3065–3071 (1999).
pubmed: 10462241
doi: 10.1016/S0264-410X(99)00145-0
Sallusto, F. & Lanzavecchia, A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 4, S127–132 (2002).
pubmed: 12110131
pmcid: 3240143
doi: 10.1186/ar567
Blander, J. M. & Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808–812 (2006).
pubmed: 16489357
doi: 10.1038/nature04596
Jegerlehner, A. et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 32, 3305–3314 (2002).
pubmed: 12555676
doi: 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J
Fischer, N. O. et al. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J. Am. Chem. Soc. 135, 2044–2047 (2013).
pubmed: 23331082
doi: 10.1021/ja3063293
de Titta, A. et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl Acad. Sci. USA 110, 19902–19907 (2013).
pubmed: 24248387
pmcid: 3856841
doi: 10.1073/pnas.1313152110
Mohsen, M. O. et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J. Control Release 251, 92–100 (2017).
pubmed: 28257987
doi: 10.1016/j.jconrel.2017.02.031
Bachmann, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451 (1993).
pubmed: 8248784
doi: 10.1126/science.8248784
Mohsen, M. O. & Bachmann, M. F. Virus-like particle vaccinology, from bench to bedside. Cell Mol. Immunol. 19, 993–1011 (2022).
pubmed: 35962190
pmcid: 9371956
doi: 10.1038/s41423-022-00897-8
de la Maza, L. M., Pal, S., Khamesipour, A. & Peterson, E. M. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect. Immun. 62, 2094–2097 (1994).
pubmed: 8168974
pmcid: 186471
doi: 10.1128/iai.62.5.2094-2097.1994
de la Maza, L. M., Darville, T. L. & Pal, S. Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go? Expert Rev. Vaccines 20, 421–35 (2021).
Mestecky, J., Russell, M. W. & Elson, C. O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179, 5633–5638 (2007).
pubmed: 17947632
doi: 10.4049/jimmunol.179.9.5633
Caldwell, H. D., Kromhout, J. & Schachter, J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31, 1161–1176 (1981).
pubmed: 7228399
pmcid: 351439
doi: 10.1128/iai.31.3.1161-1176.1981
Peterson, E. M., Zhong, G. M., Carlson, E. & de la Maza, L. M. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect. Immun. 56, 885–891 (1988).
pubmed: 3346076
pmcid: 259385
doi: 10.1128/iai.56.4.885-891.1988
Su, H., Morrison, R. P., Watkins, N. G. & Caldwell, H. D. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J. Exp. Med. 172, 203–212 (1990).
pubmed: 1694217
doi: 10.1084/jem.172.1.203
Cheng, C. et al. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). Microbes Infect. 16, 123–133 (2014).
pubmed: 24161793
doi: 10.1016/j.micinf.2013.10.012
Pal, S., Cheng, X., Peterson, E. M. & de la Maza, L. M. Mapping of a surface-exposed B-cell epitope to the variable sequent 3 of the major outer-membrane protein of Chlamydia trachomatis. J. Gen. Microbiol. 139, 1565–1570 (1993).
pubmed: 7690394
doi: 10.1099/00221287-139-7-1565
Pal, S., Fielder, T. J., Peterson, E. M. & de la Maza, L. M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect. Immun. 62, 3354–3362 (1994).
pubmed: 8039906
pmcid: 302966
doi: 10.1128/iai.62.8.3354-3362.1994
Pal, S., Tifrea, D. F., Follmann, F., Andersen, P. & de la Maza, L. M. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine 35, 1705–1711 (2017).
pubmed: 28238632
doi: 10.1016/j.vaccine.2017.02.020
Goodman, S. N. Statistics. Aligning statistical and scientific reasoning. Science 352, 1180–1181 (2016).
pubmed: 27257246
doi: 10.1126/science.aaf5406
Rubin, M. When to adjust alpha during multiple testing: a consideration of disjunction, conjunction, and individual testing. Synthese 199, 10969–11000 (2021).
doi: 10.1007/s11229-021-03276-4